Fmr LLC Boosts Stake in Immunocore Holdings plc (NASDAQ:IMCR)

Fmr LLC increased its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 0.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,836,040 shares of the company’s stock after buying an additional 23,436 shares during the quarter. Fmr LLC owned about 0.10% of Immunocore worth $150,546,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in IMCR. Alpha DNA Investment Management LLC acquired a new stake in Immunocore during the 3rd quarter worth about $411,000. HealthInvest Partners AB lifted its holdings in shares of Immunocore by 127.4% during the third quarter. HealthInvest Partners AB now owns 54,060 shares of the company’s stock worth $1,683,000 after purchasing an additional 30,282 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Immunocore by 27.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 498,221 shares of the company’s stock valued at $15,510,000 after buying an additional 107,656 shares during the last quarter. Primecap Management Co. CA increased its holdings in Immunocore by 26.7% in the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after buying an additional 520,950 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Immunocore by 7.5% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 427,152 shares of the company’s stock worth $13,297,000 after buying an additional 29,689 shares during the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research note on Thursday, October 24th. Morgan Stanley cut their price target on Immunocore from $80.00 to $74.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Oppenheimer reissued an “outperform” rating and issued a $89.00 price objective (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. UBS Group began coverage on Immunocore in a report on Thursday, October 24th. They set a “sell” rating and a $24.00 target price on the stock. Finally, Barclays decreased their price target on Immunocore from $92.00 to $66.00 and set an “overweight” rating for the company in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $69.18.

Immunocore Stock Performance

NASDAQ:IMCR opened at $32.22 on Wednesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The stock has a market capitalization of $1.61 billion, a PE ratio of -33.92 and a beta of 0.73. Immunocore Holdings plc has a fifty-two week low of $29.72 and a fifty-two week high of $76.98. The company has a fifty day moving average of $32.27 and a two-hundred day moving average of $36.18.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. The business had revenue of $80.25 million during the quarter, compared to analysts’ expectations of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company’s quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.59) earnings per share. As a group, research analysts forecast that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.